Casdin Capital’s Agios Pharmaceuticals AGIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-100,000
| Closed | -$3.33M | – | 33 |
|
|
2025
Q2 | $3.33M | Sell |
100,000
-150,000
| -60% | -$4.55M | 0.3% | 25 |
|
|
2025
Q1 | $7.33M | Hold |
250,000
| – | – | 0.6% | 26 |
|
|
2024
Q4 | $8.21M | Buy |
+250,000
| New | +$11.7M | 0.55% | 23 |
|
|
2022
Q3 | – | Sell |
-785,000
| Closed | -$17.4M | – | 38 |
|
|
2022
Q2 | $17.4M | Sell |
785,000
-1,305,000
| -62% | -$29.5M | 1.47% | 20 |
|
|
2022
Q1 | $60.8M | Hold |
2,090,000
| – | – | 2.73% | 15 |
|
|
2021
Q4 | $68.7M | Sell |
2,090,000
-75,000
| -3% | -$3.02M | 1.94% | 16 |
|
|
2021
Q3 | $99.9M | Hold |
2,165,000
| – | – | 2.49% | 15 |
|
|
2021
Q2 | $119M | Hold |
2,165,000
| – | – | 3.03% | 12 |
|
|
2021
Q1 | $112M | Sell |
2,165,000
-210,000
| -9% | -$10.4M | 3.33% | 10 |
|
|
2020
Q4 | $103M | Buy |
2,375,000
+625,000
| +36% | +$24.7M | 3.05% | 10 |
|
|
2020
Q3 | $61.3M | Buy |
1,750,000
+680,000
| +64% | +$29.8M | 2.74% | 10 |
|
|
2020
Q2 | $57.2M | Hold |
1,070,000
| – | – | 3.39% | 9 |
|
|
2020
Q1 | $38M | Buy |
1,070,000
+245,000
| +30% | +$11.3M | 4.03% | 9 |
|
|
2019
Q4 | $39.4M | Sell |
825,000
-110,000
| -12% | -$4.16M | 3.62% | 13 |
|
|
2019
Q3 | $30.3M | Buy |
935,000
+440,000
| +89% | +$18.2M | 3.14% | 13 |
|
|
2019
Q2 | $24.7M | Buy |
495,000
+160,000
| +48% | +$8.55M | 2.31% | 15 |
|
|
2019
Q1 | $22.6M | Sell |
335,000
-110,000
| -25% | -$6.41M | 2.48% | 15 |
|
|
2018
Q4 | $20.5M | Sell |
445,000
-134,776
| -23% | -$8.32M | 3.51% | 12 |
|
|
2018
Q3 | $44.7M | Buy |
579,776
+215,000
| +59% | +$17.3M | 5.43% | 4 |
|
|
2018
Q2 | $30.7M | Hold |
364,776
| – | – | 4.3% | 8 |
|
|
2018
Q1 | $29.8M | Buy |
364,776
+69,776
| +24% | +$5.39M | 5.25% | 6 |
|
|
2017
Q4 | $16.9M | Buy |
295,000
+40,000
| +16% | +$2.52M | 4.11% | 11 |
|
|
2017
Q3 | $17M | Hold |
255,000
| – | – | 4.81% | 10 |
|
|
2017
Q2 | $13.1M | Buy |
255,000
+17,500
| +7% | +$895K | 4.85% | 6 |
|
|
2017
Q1 | $13.9M | Sell |
237,500
-3,000
| -1% | -$144K | 8.18% | 4 |
|
|
2016
Q4 | $10M | Sell |
240,500
-41,943
| -15% | -$2.2M | 8.29% | 3 |
|
|
2016
Q3 | $14.9M | Buy |
282,443
+94,943
| +51% | +$4.13M | 12.08% | 1 |
|
|
2016
Q2 | $7.86M | Buy |
187,500
+39,500
| +27% | +$1.95M | 7.82% | 2 |
|
|
2016
Q1 | $6.01M | Buy |
148,000
+51,500
| +53% | +$2.2M | 6.9% | 5 |
|
|
2015
Q4 | $6.26M | Buy |
+96,500
| New | +$6.33M | 5.54% | 7 |
|
Other funds holding AGIO
FCM
BG
EAM
PBA
CC
Casdin Capital's AGIO Position: Q3 2025 in Review
Casdin Capital sold out of Agios Pharmaceuticals (AGIO) in Q3 2025, closing a stake of 100,000 shares — an estimated $3.33M sold.
Casdin Capital first reported a position in AGIO in Q4 2015 and held it in 30 quarters. The position peaked at $119M in Q2 2021. 221 funds tracked by Wall St. Rank hold AGIO as of Q3 2025.
- Casdin Capital reported no remaining Agios Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
- Casdin Capital sold 100,000 Agios Pharmaceuticals shares in Q3 2025, an estimated $3.33M.
- Casdin Capital first reported a position in Agios Pharmaceuticals in Q4 2015 and held it in 30 quarters.
- Casdin Capital's Agios Pharmaceuticals position peaked at $119M in Q2 2021.
- 221 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2025.
Based on Casdin Capital's 13F filing for Q3 2025, filed 14 Nov 2025.